{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061271","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.471408+00:00","generated_at":"2026-06-08T09:21:32.293429+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tempest Q3 net loss $6.8M; TPST-1120 shows superiority in liver cancer; cash runway into 2025","bullets":["Net loss $6.8M ($0.48/share) vs $8.9M ($0.66) in Q3 2022; R&D expense fell to $4.2M from $6.0M.","Cash $11.1M at Sep 30; after $23.9M ATM net proceeds, preliminary cash $32.8M extending runway into 2025.","TPST-1120 triplet arm cORR 30% vs 13.3% control; median PFS 7 mo vs 4.27 mo (HR 0.7); median OS not reached vs 15.1 mo (HR 0.59).","Plan to advance TPST-1120 into registrational study in first-line HCC, likely with a partner.","Adopted limited-duration stockholder rights plan on Oct 10, 2023 to deter hostile accumulation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061271","json":"https://secwatch.observer/filing/0000950170-23-061271.json","markdown":"https://secwatch.observer/filing/0000950170-23-061271.md","text":"https://secwatch.observer/filing/0000950170-23-061271.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023061271/0000950170-23-061271-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023061271/tpst-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:21:32.293429+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"730de07783a16c43e9decf428516b51a556ca1e1","claim":"Tempest Therapeutics, Inc. reported the nine months ended September 30, 2023 results: net income $22.0 million, EPS $1.57 per share.","evidence_excerpt":"Net loss and net loss per share for the nine months ended September 30, 2023 were $22.0 million and $1.57, respectively, compared to $26.6 million and $2.46, respectively, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023061271/0000950170-23-061271-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2023"},{"label":"Net income","value":"$22.0 million"},{"label":"EPS","value":"$1.57 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"dde26323283fb29c10e93a09021e22cde4239f00","claim":"Tempest Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income $6.8 million, EPS $0.48 per share.","evidence_excerpt":"Net loss and net loss per share for the quarter ended September 30, 2023 were $6.8 million and $0.48, respectively, compared to $8.9 million and $0.66, respectively, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023061271/0000950170-23-061271-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"$6.8 million"},{"label":"EPS","value":"$0.48 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}